SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer. In this new role, Dr. Ben will oversee BBOT’s ongoing clinical programs, driving the development and delivery of new therapies for cancer patients.

加利福尼亚州南旧金山——（商业新闻短讯）——TheRas，Inc.d/b/a BridgeBio Oncology Therapeutics（“BBOT”或“公司”），一家临床阶段精准肿瘤学公司，宣布任命医学博士Yong（Ben）Ben为首席医疗和发展官。在这个新角色中，本博士将监督BBOT正在进行的临床项目，推动癌症患者新疗法的开发和交付。

These include BBO-8520, BBO-10203, and BBO-11818..

这些包括BBO-8520、BBO-10203和BBO-11818。。

“Ben is a highly accomplished leader with an outstanding record in drug development,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “His extensive experience in accelerating the development of innovative cancer therapeutics will be invaluable as we advance our clinical programs. We are thrilled to have him join our team and look forward to working together to bring new treatments to patients in need.”.

BBOT首席执行官EliWallace博士说：“Ben是一位非常有成就的领导者，在药物开发方面有着出色的记录。”。“随着我们临床项目的推进，他在加速创新癌症治疗方法开发方面的丰富经验将是无价的。我们很高兴他加入我们的团队，并期待着共同努力，为有需要的患者带来新的治疗方法。”。

Dr. Ben joined BBOT in September 2024, bringing more than 25 years of experience in research and development across the entire life cycle of drug development, from early- to late-stage and through commercialization. He has been instrumental in the approval of more than 10 molecules in more than 20 indications, covering various modalities including small molecules, biologics, and antibody-drug conjugates (ADCs)..

Ben博士于2024年9月加入BBOT，在药物开发的整个生命周期，从早期到晚期以及通过商业化，带来了超过25年的研发经验。他帮助批准了20多种适应症中的10多种分子，涵盖了各种方式，包括小分子，生物制剂和抗体-药物偶联物（ADC）。。

Prior to joining BBOT, Dr. Ben was a Venture Partner at Eight Roads Venture, a venture capital firm backed by Fidelity, and served as acting Chief Executive Officer of AlphaGen, a radiopharmaceutical biotech incubated by ERVC and F-Prime Capital. His previous roles include Chief Medical Officer, solid tumors, at BeiGene from 2019 to 2022, and Chief Medical Officer at BioAtla from 2017 to 2019.

在加入BBOT之前，Ben博士是由Fidelity支持的风险投资公司八路风险投资公司的风险合伙人，并担任AlphaGen的代理首席执行官，AlphaGen是由ERVC和F-Prime capital孵化的放射性药物生物技术。他之前的职务包括2019年至2022年在BeiGene担任实体瘤首席医疗官，以及2017年至2019年在BioAtla担任首席医疗官。

At AstraZeneca, Dr. Ben was the Global Clinical Leader of Immuno-Oncology Clinical Development, where he led the approval of IMFINZI® (durvalumab) in urothelial cancer. His career highlights also include the approval of NINLARO® (ixazomib) in multiple myeloma at Millennium Pharmaceuticals and INLYTA® (axitinib) in renal cancer at Pfizer.

在阿斯利康，本博士是免疫肿瘤学临床开发的全球临床领导者，在那里他领导了尿路上皮癌IMFINZI®（durvalumab）的批准。他的职业生涯亮点还包括Millennium Pharmaceuticals批准NINLARO®（ixazomib）治疗多发性骨髓瘤，以及辉瑞公司批准INLYTA®（axitinib）治疗肾癌。

He also currently sits on the board at Corbus Pharmaceuticals..

他目前也是Corbus Pharmaceuticals的董事会成员。。

Dr. Ben began his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. He holds a medical degree from Norman Bethune College of Medicine, and an MBA from the University of California, San Diego.

本博士在北京协和医院开始了他的外科肿瘤学家生涯，并在加利福尼亚太平洋医学中心完成了博士后奖学金。。

“I am excited to join Eli Wallace and the talented team at BBOT,” said Dr. Ben. “BridgeBio Oncology Therapeutics is the perfect setting to apply my experience in drug development to accelerate new, meaningful therapeutics to patients afflicted with cancer. I look forward to contributing to the advancement of our clinical programs and making a significant impact on patient care.”.

本博士说：“我很高兴能加入EliWallace和BBOT的天才团队。”。“BridgeBio Oncology Therapeutics是将我在药物开发方面的经验应用于加速对癌症患者进行新的有意义的治疗的完美环境。我期待着为我们的临床计划的进步做出贡献，并对患者护理产生重大影响。”。

About TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT)

关于TheRas，Inc.d/b/a BridgeBio Oncology Therapeutics（BBOT）

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.

BridgeBio Oncology Therapeutics（BBOT）是一家临床阶段的生物制药公司，致力于开发针对RAS和PI3K恶性肿瘤的新一代小分子治疗药物。BBOT最初是作为BridgeBio的子公司成立的，于2024年与外部投资者完成了2亿美元的私人融资，目标是改善由人类肿瘤中两种最普遍的致癌基因驱动的癌症患者的预后。

For more information visit bridgebiooncology.com..

有关更多信息，请访问BridgeBioncology.com。。